ARTICLE | Company News

Apeiron Biologics, Children's Cancer Research deal

June 27, 2011 7:00 AM UTC

The Children's Cancer Research Institute (Vienna, Austria) and the European Neuroblastoma Research Network (SIOPEN) granted Apeiron exclusive, worldwide rights to develop and commercialize ch14.18, a chimeric mAb against GD2. Apeiron will provide financial support for the ongoing, European Phase III trial of ch14.18 in high-risk neuroblastoma patients. The institute and SIOPEN also will receive an upfront payment and are eligible for milestones and royalties. Financial details were not disclosed...